Overview

Pharmacologic Effect for Female Overactive Bladder Syndrome: Mirabegron Versus Solifenacin

Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
To assess the impact of mirabegron versus solifenacin on psychological distress, sexual function, bladder wall thickness and bladder blood flow.
Phase:
Phase 3
Details
Lead Sponsor:
Far Eastern Memorial Hospital
Treatments:
Mirabegron
Solifenacin Succinate